Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Fibrosis × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 15 Carcinoma, Renal Cell 8 Neuroendocrine Tumors 6 Neoplasm Metastasis 3 Kidney Neoplasms 3 Tuberous Sclerosis 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Neoplasms 2 Gastro-enteropancreatic neuroendocrine tumor 2 Carcinoma 2 Carcinoid Tumor 2 von Hippel-Lindau Disease 1 Tuberous Sclerosis Complex-associated Refractory Seizures 1 Thymus Neoplasms 1 Stomach Diseases 1 Skin Neoplasms 1 Seizures 1 Renal Cell Cancer Metastatic 1 Polycystic Kidney, Autosomal Dominant 1 Malignant Carcinoid Syndrome 1 HER2+ Breast Cancer 1 Fibrosis 1 Digestive System Neoplasms 1 Diffuse Intrinsic Pontine Glioma 1 Cysts 1 Carcinoma, Hepatocellular 1 Breast Neoplasms, Male 1 Breast Cancer Metastatic 1 Astrocytoma 1

Interventions

esmolol 1 epigallocatechin gallate 1 contrast agent BR1 1 alpha-Tocopherol 1 Viusid 1 Sonazoid 1 Sodium Chloride 1 Simvastatin 1 Pentoxifylline 1 Iodides 1 Everolimus 1 Dietary Supplements 1 Catechin 1 2-chloro-N(6)-(3-iodobenzyl)adenosine-5'-N-methyluronamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02134899 2018-12-10

EVERKYSTE

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed

Cysts, Fibrosis, Polycystic Kidney, Autosomal Dominant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡